ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Impact of Risk Evaluation and Mitigation Strategies in Oncology

Jessica DeMartino, PhD
Published: Wednesday, Mar 02, 2011
The management of risk in medicine is emerging as a priority topic for numerous stakeholders, including patients, providers (physicians, other prescribers, and pharmacists), specialty pharmacies, industry, and government organizations. The US Food and Drug Administration (FDA) was given the authority in 2008 under the FDA Amendments Act to require manufacturers to develop risk evaluation and mitigation strategies (REMS) both for existing drugs and drugs in development when it is determined that special action is needed to make certain that the benefits of a drug outweigh its risks.

When used fittingly, REMS can ensure safe use of prescribed drugs, including appropriate selection, monitoring, and education. However, applying REMS to oncology and supportive-care drugs must be done carefully. The risks associated with treating oncology patients must be balanced against concerns about limiting access to lifesaving drugs.

Although some REMS are relatively simple (eg, only require provision of a medication guide), other REMS have numerous components and require actions by prescribers, pharmacists, pharmacies, and patients. Complex REMS must be designed so that they do not impose an inappropriate burden on patients, physicians, pharmacists, and other healthcare providers. In a March 2010 National Comprehensive Cancer Network (NCCN) Trends Survey, opinions of oncology providers and pharmacists were collected on the topic of REMS.1 As noted, REMS may result in significantly more work for prescribers and dispensers of drugs with REMS, making it less likely for a drug with a complex strategy to be used. Results Impact of Risk Evaluation and Mitigation Strategies in Oncology By Jessica DeMartino, PhD from the NCCN Trends Survey supported this notion, as 60% of respondents agreed that REMS will drive utilization toward drugs without REMS. Risk evaluation and mitigation strategies must not compel providers to use alternative drugs that are not the best treatment option because of the administrative burden of drugs with REMS.

As the new REMS paradigm develops, the practical implications of REMS policies and processes must be carefully considered so that REMS are implemented in a feasible manner. Many providers worry that REMS will interfere with their care of patients. In fact, 55% of the NCCN Trends Survey respondents agreed that REMS will interfere with the provision of care. Ideally, all providers should have the ability to evaluate risks, benefits, and appropriate use of medications, and inform and educate their patients. The majority of providers do not need government oversight to ensure that they are prescribing appropriate medications. Providers must feel they have the autonomy to provide the best care possible for oncology patients.

Within oncology there are drugs, including several supportive-care medications, that currently have associated REMS. Availability of and access to these drugs are essential for patients with serious and life-threatening illnesses. In addition, the proposed classwide REMS for long-acting and extended-release opioids is particularly relevant to cancer care. Pain is one of the most common symptoms associated with cancer. Pain occurs in approximately one-quarter of patients with newly diagnosed malignancies, one-third of patients undergoing treatment, and three-quarters of patients with advanced disease.2 Unrelieved pain denies patients comfort and greatly affects their activities, motivation, interactions with family and friends, and overall quality of life. Pain management and appropriate access to long-acting and extended-release opioids are vitally important to cancer patients.

An additional example of REMS in oncology is the ESA APPRISE Oncology Program.3 This program was developed because of recent safety concerns about the use of erythropoiesis-stimulating agents (ESAs), including the risk of increased tumor growth, decreased survival, and increased cardiovascular side effects. Healthcare professionals who treat cancer patients and wish to prescribe ESAs must register and maintain active enrollment in the ESA APPRISE Oncology Program; complete a special training module; provide medication guides; discuss the risks, benefits, and FDA-approved uses of ESAs with patients before beginning treatment; and document this discussion. For many advanced-stage cancer patients, the risks that the ESA APPRISE Oncology Program warns of are inconsequential compared with their overall prognosis. In the March 2010 NCCN Trends Survey focusing on REMS, 6% of physicians (all oncologists) reported that they are not registered in the ESA APPRISE Oncology Program and do not plan to register because of the associated administrative burden. Will these types of REMS programs drive physicians away from utilizing appropriate medications due to the increased workload? The application of REMS must balance feasibility for providers and pharmacists with the FDA's goal of mitigating the risks of a drug.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing Chemotherapy Induced Nausea and VomitingOct 31, 20182.0
Publication Bottom Border
Border Publication
x